Methods for the treatment of muscle wasting and bone disease using a novel hybrid ACTRIIB ligand trap protein

摘要

This disclosure describes a novel hybrid soluble ActRIIB-ECD polypeptide. The present disclosure relates to the use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of a disorder or condition selected from the group consisting of muscle wasting, bone disease, metabolic, fibrotic, autoimmune / inflammatory, cardiovascular disease, cancer or cancer, chronic kidney disease (CKD), arthritis, , Organ or tissue transplant rejection, anemia, pain, and / or aging. Additionally, the disclosure provides methods for inducing stem cell growth for tissue repair or long term regeneration of a subject. The method described above comprises administering to the subject a therapeutically effective amount of a hybrid ActRIIB ligand trap polypeptide. The present disclosure also provides pharmaceutical compositions comprising a hybrid ActRIIB ligand trap polypeptide.